期刊文献+

比阿培南在健康受试者体内的药物动力学研究 被引量:2

Pharmacokinetics of single dose Biapenem by intravenous drip in healthy volunteers
原文传递
导出
摘要 目的采用RP-HPLC法测定人血浆中比阿培南的浓度,研究比阿培南在健康受试者体内的药动学。方法 24名健康志愿者分组接受单次(150、300、600 mg)静脉滴注比阿培南,应用RP-HPLC法测定血药浓度,通过DAS2.0药动学软件计算药动学参数。结果受试者静注单剂量低、中、高比阿培南的t1/2β分别为2.13±1.58、1.23±0.17、1.21±0.16 h,Tm ax分别为0.86±0.68、0.68±0.05、0.68±0.05 h,Cm ax分别为7.75±2.69、17.67±2.62、33.31±7.14 mg.L-1,AUC(0-t)分别为12.66±2.74、26.79±3.74、50.50±7.77 mg.h.L-1。结论注射用比阿培南在健康人体内的药动学符合二室模型特征,Cm ax和AUC与给药剂量呈线性相关。 OBJECTIVE To develop an HPLC method for determination of Biapenem in human plasma to study the pharmacokinetics of Biapenem in Chinese healthy volunteers.METHODS 24 healthy volunteers were randomly divided into groups,and were administered a single dose(150,300,600 mg) of Biapenem by intravenous drip.Biapenem in plasma was determined by RP-HPLC method,and the pharmacokinetic parameters were calculated by DAS 2.0 software.RESULTS The main pharmacokinetic parameters of a single dose(150、300、600 mg)were as fol...
出处 《华西药学杂志》 CAS CSCD 北大核心 2010年第6期715-717,共3页 West China Journal of Pharmaceutical Sciences
关键词 比阿培南 药物动力学 高效液相色谱 血药浓度 Biapenem Pharmacokinetics HPLC Plasma concentration
  • 相关文献

参考文献3

二级参考文献48

  • 1Petersen P J, Jaeobus N V, Weiss W J, et al. In vitro and in vivo activities of LJC10, 627, a new carbapenem with stability to dehydropeptidase Ⅰ [J]. Antimicrob Agents Chemother, 1991,35(1) : 203-207.
  • 2Malanoski G J, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of Gram-positive and Gram-negative bacteria [J]. Antimicrob Agents Chemother,1993,37(9) :2009-2016.
  • 3Koeppe P, Hoeffler D, Fitzen B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function [J]. Arzneimittel-Forschung, 1997,47(11):1250-1256.
  • 4Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects [J]. Antimicrob Agents Chemother , 1998,42(6) : 1433-1436.
  • 5赵香兰.临床药代动力学[M].郑州:郑州大学出版社,2003年:113-187.
  • 6Nagashima S, Kozawa O, Otsuka T, et al. Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis [J]. J Antimicrob Chemother , 2000,46 (5) :839-842.
  • 7Nakashima M, Uematsu T, Ueno K, et al. Phase Ⅰ study of L-627, biapenem, a new parenteral earbapenem antibiotic [J]. Int J Clin Pharmacol Ther Toxicol,1993,31(2): 70-76.
  • 8Hoban D J,Jones R N,Yamane N, et al. In viuo activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and mempenem against aerobic pathogens isolated worldwide [J]. Diagn Microbiol Infect Dis, 1993, 17(4):299.
  • 9Vessillier S, Docquier J D. Overproduction and biochemical characterization of the chryseobacterium meningosepticum BlaB Metallo- β - Lactamase [ J ]. Antimicrob Agents Chemother, 2002,46 (6) : 1921.
  • 10Igari J, Watanabe M, Uehara N, et al. Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems ) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents [J]. Jpn J Antibiot ,2000,53(3) :157.

共引文献52

同被引文献27

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部